ST-segment elevation myocardial infarction in Kawasaki disease: A case report and review of literature

Table 1 Antithrombotic therapy in the primary prevention settings of Kawasaki disease

Agent	Indication	Dose	Monitoring	Mechanism of action
Aspirin	Initial therapy for prevention of thrombosis.(Z score ≥ 2.5)	3-5 mg/kg/day	-	Cyclooxygenase-1 inhibitor
Clopidogrel	Resistance to aspirin or aspirin allergy. Dual-antiplatelet therapy for thromboprophylaxis	0.2-1.0 mg/kg/day	-	P2Y12 inhibitor
Prasugrel/ticagrelor	NA	NA	NA	P2Y12 inhibitor
Warfarin	Thromboprophylaxis for large or giant aneurysm. (Z score > 10)		INR 2-3	Vitamin K antagonist
LMWH	Thromboprophylaxis for large or giant aneurysm.(Z score > 10)	Dosage varies according to age and agent	-	Active antithrombin III

NA: Not applicable; INR: International normalized ratio; LMWH: Low molecular weight heparin.